Levosimendan in Europe and China: An Appraisal of Evidence and Context
The calcium sensitiser levosimendan (SIMDAX; Orion Pharma) has been in clinical use for the management of acute heart failure and a range of related syndromes in many countries around the world for two decades. More recently, levosimendan has become available in China. The authors have examined the...
Guardado en:
Autores principales: | , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Radcliffe Medical Media
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d6ea5947bafb402f8d01baee6e6bf6a7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:d6ea5947bafb402f8d01baee6e6bf6a7 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:d6ea5947bafb402f8d01baee6e6bf6a72021-12-04T16:05:18ZLevosimendan in Europe and China: An Appraisal of Evidence and Context10.15420/ecr.2021.411758-37641758-3756https://doaj.org/article/d6ea5947bafb402f8d01baee6e6bf6a72021-11-01T00:00:00Zhttps://www.ecrjournal.com/articleindex/ecr.2021.41https://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764The calcium sensitiser levosimendan (SIMDAX; Orion Pharma) has been in clinical use for the management of acute heart failure and a range of related syndromes in many countries around the world for two decades. More recently, levosimendan has become available in China. The authors have examined the profile of levosimendan in clinical trials conducted inside and outside China and grouped the findings under six headings: effects on haemodynamics, effects on natriuretic peptides, effect on symptoms of heart failure, renal effects, effect on survival, and safety profile. Their conclusions are that under each of these headings there are reasonable grounds to expect that the effects and clinical benefits established in trials and with wider clinical use in Europe and elsewhere will accrue also to Chinese patients. Therefore, the authors are confident that global experience with levosimendan provides a reliable guide to its optimal use and likely therapeutic effects in patients in China.Xiangqing KongXinqun HuBaotong HuaFrancesco FedeleDimitrios FarmakisPiero PolleselloRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 16, Iss , Pp - (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Diseases of the circulatory (Cardiovascular) system RC666-701 |
spellingShingle |
Diseases of the circulatory (Cardiovascular) system RC666-701 Xiangqing Kong Xinqun Hu Baotong Hua Francesco Fedele Dimitrios Farmakis Piero Pollesello Levosimendan in Europe and China: An Appraisal of Evidence and Context |
description |
The calcium sensitiser levosimendan (SIMDAX; Orion Pharma) has been in clinical use for the management of acute heart failure and a range of related syndromes in many countries around the world for two decades. More recently, levosimendan has become available in China. The authors have examined the profile of levosimendan in clinical trials conducted inside and outside China and grouped the findings under six headings: effects on haemodynamics, effects on natriuretic peptides, effect on symptoms of heart failure, renal effects, effect on survival, and safety profile. Their conclusions are that under each of these headings there are reasonable grounds to expect that the effects and clinical benefits established in trials and with wider clinical use in Europe and elsewhere will accrue also to Chinese patients. Therefore, the authors are confident that global experience with levosimendan provides a reliable guide to its optimal use and likely therapeutic effects in patients in China. |
format |
article |
author |
Xiangqing Kong Xinqun Hu Baotong Hua Francesco Fedele Dimitrios Farmakis Piero Pollesello |
author_facet |
Xiangqing Kong Xinqun Hu Baotong Hua Francesco Fedele Dimitrios Farmakis Piero Pollesello |
author_sort |
Xiangqing Kong |
title |
Levosimendan in Europe and China: An Appraisal of Evidence and Context |
title_short |
Levosimendan in Europe and China: An Appraisal of Evidence and Context |
title_full |
Levosimendan in Europe and China: An Appraisal of Evidence and Context |
title_fullStr |
Levosimendan in Europe and China: An Appraisal of Evidence and Context |
title_full_unstemmed |
Levosimendan in Europe and China: An Appraisal of Evidence and Context |
title_sort |
levosimendan in europe and china: an appraisal of evidence and context |
publisher |
Radcliffe Medical Media |
publishDate |
2021 |
url |
https://doaj.org/article/d6ea5947bafb402f8d01baee6e6bf6a7 |
work_keys_str_mv |
AT xiangqingkong levosimendanineuropeandchinaanappraisalofevidenceandcontext AT xinqunhu levosimendanineuropeandchinaanappraisalofevidenceandcontext AT baotonghua levosimendanineuropeandchinaanappraisalofevidenceandcontext AT francescofedele levosimendanineuropeandchinaanappraisalofevidenceandcontext AT dimitriosfarmakis levosimendanineuropeandchinaanappraisalofevidenceandcontext AT pieropollesello levosimendanineuropeandchinaanappraisalofevidenceandcontext |
_version_ |
1718372704268058624 |